Nancy R. Cook, ScD; I-Min Lee, ScD; Shumin M. Zhang, ScD; M. Vinayaga Moorthy, PhD; Julie E. Buring, ScD
Note: Aspirin and aspirin placebo were provided by Bayer HealthCare. Vitamin E and vitamin E placebo were provided by the Natural Source Vitamin E Association, Chicago, Illinois.
Grant Support: By grants HL043851, HL080467, HL099355, and CA047988 from the National Heart, Lung, and Blood Institute and the National Cancer Institute, Bethesda, Maryland.
Potential Conflicts of Interest: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M12-2816.
Reproducible Research Statement: Study protocol and statistical code: Available from the authors upon written request. Data set: Not available.
Requests for Single Reprints: Nancy R. Cook, ScD, Brigham and Women's Hospital, 900 Commonwealth Avenue East, Boston, MA 02215; e-mail, email@example.com.
Current Author Addresses: Drs. Cook, Lee, Zhang, Moorthy, and Buring: Brigham and Women's Hospital, 900 Commonwealth Avenue East, Boston, MA 02215.
Author Contributions: Conception and design: N.R. Cook, I.M. Lee, S.M. Zhang, J.E. Buring.
Analysis and interpretation of the data: N.R. Cook, S.M. Zhang, M.V. Moorthy.
Drafting of the article: N.R. Cook.
Critical revision of the article for important intellectual content: N.R. Cook, I.M. Lee, S.M. Zhang, J.E. Buring.
Final approval of the article: N.R. Cook, I.M. Lee, S.M. Zhang, M.V. Moorthy, J.E. Buring.
Provision of study materials or patients: J.E. Buring.
Statistical expertise: N.R. Cook.
Obtaining of funding: I.M. Lee, S.M. Zhang, J.E. Buring.
Administrative, technical, or logistic support: I.M. Lee, J.E. Buring.
Collection and assembly of data: I.M. Lee, S.M. Zhang, M.V. Moorthy, J.E. Buring.
Recent evidence suggests that daily aspirin use decreases cancer risk, particularly for colorectal cancer, but evidence for alternate-day use is scant.
To examine the association between long-term, alternate-day, low-dose aspirin and cancer in healthy women.
Observational follow-up of a randomized trial.
Female health professionals.
39 876 women aged 45 years or older in the Women's Health Study (ClinicalTrials.gov: NCT00000479), 33 682 of whom continued observational follow-up.
100 mg of alternate-day aspirin or placebo through March 2004, with a median 10-year follow-up. Posttrial follow-up continued through March 2012.
A total of 5071 cancer cases (including 2070 breast, 451 colorectal, and 431 lung cancer cases) and 1391 cancer deaths were confirmed. Over the entire follow-up, aspirin had no association with total (hazard ratio [HR], 0.97 [95% CI, 0.92 to 1.03]; P = 0.31), breast (HR, 0.98 [CI, 0.90 to 1.07]; P = 0.65), or lung (HR, 1.04 [CI, 0.86 to 1.26]; P = 0.67) cancer. Colorectal cancer was reduced in the aspirin group (HR, 0.80 [CI, 0.67 to 0.97]; P = 0.021), primarily for proximal colon cancer (HR, 0.73 [CI, 0.55 to 0.95]; P = 0.022). The difference emerged after 10 years, with a posttrial reduction of 42% (HR, 0.58 [CI, 0.42 to 0.80]; P < 0.001). There was no extended effect on cancer deaths or colorectal polyps. More gastrointestinal bleeding (HR, 1.14 [CI, 1.06 to 1.22]; P < 0.001) and peptic ulcers (HR, 1.17 [CI, 1.09 to 1.27]; P < 0.001) occurred in the aspirin group.
Not all women received extended follow-up, and posttrial ascertainment bias cannot be ruled out. Gastrointestinal bleeding, peptic ulcers, and polyps were self-reported during extended follow-up.
Long-term use of alternate-day, low-dose aspirin may reduce risk for colorectal cancer in healthy women.
National Institutes of Health.
Cook NR, Lee I, Zhang SM, Moorthy MV, Buring JE. Alternate-Day, Low-Dose Aspirin and Cancer Risk: Long-Term Observational Follow-up of a Randomized Trial. Ann Intern Med. ;159:77–85. doi: 10.7326/0003-4819-159-2-201307160-00002
Download citation file:
Published: Ann Intern Med. 2013;159(2):77-85.
Cancer Screening/Prevention, Gastroenterology/Hepatology, Hematology/Oncology, Prevention/Screening.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use